Contineum Therapeutics, Inc. (CTNM): who owns it and who trades it
As of Nov 16, 2026, CTNM insiders reported 30 open-market sales worth $1.9M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel S. Lorrain (Chief Scientific Officer), with $1.1M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Contineum Therapeutics
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CTNM
102 funds and institutions reported CTNM shares worth $504M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 12.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Montanova Capital, LLC | 2.84M | 12.30% | $46.6M | No change |
| Jupiter Topco LLC | 2.73M | 11.84% | $44.8M | New |
| BlackRock, Inc. | 2.06M | 8.94% | $33.8M | +209% |
| Johnson & Johnson | 1.98M | 8.57% | $32.4M | No change |
| Franklin Resources Inc | 1.84M | 7.96% | $30.1M | No change |
| Balyasny Asset Management L.P. | 1.52M | 6.59% | $25M | -10% |
| Vanguard Capital Management LLC | 1.32M | 5.72% | $21.7M | +9% |
| Perceptive Advisors LLC | 1.26M | 5.44% | $20.6M | No change |
| FMR LLC (Fidelity) | 1.04M | 4.50% | $17M | +28% |
| Millennium Management LLC | 931,709 | 4.03% | $15.3M | -39% |
| Great Point Partners LLC | 921,481 | 3.99% | $15.1M | +15% |
| Longaeva Partners L.P. | 812,757 | 3.52% | $13.3M | +11% |
| Ikarian Capital, LLC | 807,874 | 3.50% | $13.2M | No change |
| Sectoral Asset Management Inc | 727,587 | 3.15% | $11.9M | No change |
| Geode Capital Management, LLC | 693,188 | 3.00% | $11.4M | +146% |
| Hhlr Advisors, Ltd. | 669,337 | 2.90% | $11M | No change |
| Red Tree Management, LLC | 638,158 | 2.76% | $10.5M | No change |
| Versant Venture Management, LLC | 542,628 | 2.35% | $8.9M | No change |
| Goldman Sachs Group Inc | 497,255 | 2.15% | $8.2M | +62% |
| Boxer Capital Management, LLC | 494,000 | 2.14% | $8.1M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CTNM insiders reported $0 of open-market purchases and $1.9M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone | CEO | Sale plan | 2,500 | $16.46 | $41.1K | Form 4 |
| Aug 3, 2026 | Carmine N. Stengone | CEO | Sale plan | 2,500 | $16.01 | $40K | Form 4 |
| Jul 9, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 25 | $16.00 | $400 | Form 4 |
| Jul 8, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 1,015 | $16.00 | $16.2K | Form 4 |
| Jul 8, 2026 | Carmine N. Stengone | CEO | Sale plan | 2,500 | $16.00 | $40K | Form 4 |
| Jul 1, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 2,501 | $16.24 | $40.6K | Form 4 |
| Jul 1, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 5,852 | $15.67 | $91.7K | Form 4 |
| Jun 30, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 28,826 | $16.04 | $462K | Form 4 |
| Jun 30, 2026 | Tim Watkins | CMO & Head of Developmen | Sale plan | 10,833 | $16.02 | $174K | Form 4 |
| Jun 30, 2026 | Carmine N. Stengone | CEO | Sale plan | 10,000 | $16.01 | $160K | Form 4 |
| Jun 1, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 4,170 | $13.16 | $54.9K | Form 4 |
| May 1, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 300 | $13.84 | $4.2K | Form 4 |
| May 1, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 3,870 | $13.06 | $50.5K | Form 4 |
| Apr 6, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 4,170 | $13.43 | $56K | Form 4 |
| Mar 2, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 4,170 | $15.01 | $62.6K | Form 4 |
| Mar 2, 2026 | Tim Watkins | CMO & Head of Developmen | Sale plan | 3,611 | $15.02 | $54.2K | Form 4 |
| Feb 25, 2026 | Carmine N. Stengone | CEO | Sale plan | 2,700 | $16.02 | $43.3K | Form 4 |
| Feb 25, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 3,824 | $16.01 | $61.2K | Form 4 |
| Feb 24, 2026 | Carmine N. Stengone | CEO | Sale plan | 4,400 | $16.02 | $70.5K | Form 4 |
| Feb 24, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 4,300 | $16.03 | $68.9K | Form 4 |
| Feb 19, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 100 | $16.00 | $1.6K | Form 4 |
| Feb 11, 2026 | Carmine N. Stengone | CEO | Sale plan | 400 | $16.00 | $6.4K | Form 4 |
| Feb 3, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 3,000 | $14.82 | $44.5K | Form 4 |
| Feb 3, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 1,170 | $15.25 | $17.8K | Form 4 |
| Jan 28, 2026 | Tim Watkins | CMO & Head of Developmen | Sale plan | 2,800 | $14.09 | $39.5K | Form 4 |
| Jan 28, 2026 | Tim Watkins | CMO & Head of Developmen | Sale plan | 811 | $14.48 | $11.7K | Form 4 |
| Jan 5, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 3,670 | $10.35 | $38K | Form 4 |
| Jan 5, 2026 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 500 | $11.13 | $5.6K | Form 4 |
| Dec 29, 2025 | Tim Watkins | CMO & Head of Developmen | Sale plan | 3,611 | $12.06 | $43.5K | Form 4 |
| Dec 23, 2025 | Daniel S. Lorrain | Chief Scientific Officer | Sale plan | 4,170 | $12.23 | $51K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Daniel S. Lorrain | Chief Scientific Officer | – | $1.1M | Jul 9, 2026 |
| Carmine N. Stengone | CEO and President, Director | – | $401K | Sep 8, 2026 |
| Tim Watkins | CMO & Head of Development | – | $323K | Jun 30, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CTNM short interest
3.70M CTNM shares are sold short. Over the last 12 reports the number of shares short went up 161%.
As of Oct 30, 2026, 3.70M CTNM shares were sold short, up 1.1% from the report before. At the average daily volume of 874,802 shares, buying them all back would take about 4.2 trading days (days to cover).
Shares short
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.70M | – | +1% | 874,802 | 4.2 |
| Oct 15, 2026 | 3.66M | – | +19% | 1.64M | 2.2 |
| Sep 30, 2026 | 3.07M | – | +26% | 847,470 | 3.6 |
| Sep 15, 2026 | 2.44M | – | +4% | 352,131 | 6.9 |
| Aug 31, 2026 | 2.34M | – | +0% | 582,694 | 4.0 |
| Aug 14, 2026 | 2.34M | – | -17% | 524,037 | 4.5 |
| Jul 31, 2026 | 2.82M | – | +15% | 208,549 | 13.5 |
| Jul 15, 2026 | 2.44M | – | +14% | 333,697 | 7.3 |
| Jun 30, 2026 | 2.14M | – | +29% | 720,371 | 3.0 |
| Jun 15, 2026 | 1.65M | – | +16% | 217,886 | 7.6 |
| May 29, 2026 | 1.43M | – | +1% | 152,955 | 9.4 |
| May 15, 2026 | 1.42M | 6.14% | -12% | 210,249 | 6.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Contineum Therapeutics company events
Contineum Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Sep 14, 2026AnnouncementContineum Therapeutics, Inc. issued a press release in which it reported the results of the MOONLIGHT-1 Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of JNJ-5120/PIPE-307 as a monotherapy in adult participants with major depressive disorder. Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jul 13, 2026AnnouncementShared information with investors. Filing
- Jun 26, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 30, 2026AnnouncementThe Company announced topline data from its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain. Filing
- Mar 5, 2026AnnouncementAs previously reported, on May 14, 2025, the Company entered into a Sales Agreement with Leerink Partners LLC, pursuant to which the Company may from time to time issue and sell through Leerink Partners, acting as the Company’s agent, up to $75 million of shares of the Company’s Class A common… Filing
- Jan 26, 2026LeadershipThe Board of Directors of Contineum Therapeutics, Inc. approved the Continuem Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan. Filing
- Dec 15, 2025AgreementContineum Therapeutics, Inc., a Delaware corporation, entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC, acting as representatives of the several underwriters named in the Underwriting Agreement, relating to the sale of 7,346,938 shares of the Company’s… Filing
- Dec 11, 2025AnnouncementThe Company submitted the details of its global Phase 2 clinical trial of PIPE-791 to treat patients with idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System (PRS). Filing
- Nov 20, 2025AnnouncementContineum Therapeutics, Inc. issued a press release in which it reported topline data from its Phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Contineum Therapeutics financials
Famous investors that hold CTNM
4 of the 50 well-known investors we track reported holding CTNM in their latest 13F filing. The largest position is Israel Englander's, worth $10.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 775,324 | $10.4M | 0.0% | -17% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 221,692 | $3M | 0.0% | -44% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 23,550 | $316K | 0.0% | -9% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 15,500 | $208K | 0.0% | -77% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named CTNM in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 7.3% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G/A | 7.3% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 4.6% |
| Nov 16, 2026 | JANUS HENDERSON GROUP Ltd. | 13G/A | 4.6% |
| Nov 6, 2026 | Johnson & Johnson Innovation - JJDC, Inc. | 13G/A | 5.6% |
| Nov 6, 2026 | Johnson & Johnson Innovation - JJDC, Inc. | 13G/A | 5.6% |
| Nov 5, 2026 | FMR LLC | 13G | 7.9% |
| Nov 5, 2026 | FMR LLC | 13G | 7.9% |
| Oct 28, 2026 | Squadron Master Fund LP | 13G | 5.1% |
| Oct 28, 2026 | Squadron Master Fund LP | 13G | 5.1% |
| Oct 28, 2026 | Franklin Templeton, Inc. | 13G/A | 5.2% |
| Oct 28, 2026 | Franklin Templeton, Inc. | 13G/A | 5.2% |
| Oct 22, 2026 | Trails Edge Capital Partners, LP | 13G | 5.1% |
| Oct 22, 2026 | Trails Edge Capital Partners, LP | 13G | 5.1% |
Questions about Contineum Therapeutics, Inc. (CTNM) stock
Who owns the most CTNM stock?
The largest reported owner of Contineum Therapeutics, Inc. (CTNM) is Montanova Capital, LLC, with 12.3% of the company. In total, 102 funds and institutions reported holding CTNM at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CTNM insiders buying or selling?
In the last 12 months, CTNM insiders reported no open-market purchases and 30 sales worth $1.9M. The latest trade was on Sep 8, 2026. See every trade.
What is the short interest in CTNM?
As of Oct 30, 2026, 3.70M CTNM shares were sold short, up 1.1% from the report before. At the average daily volume of 874,802 shares, buying them all back would take about 4.2 trading days (days to cover). See the history.
Which famous investors hold CTNM?
4 of the 50 well-known investors we track reported CTNM in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $10.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.